Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease

Neurobiology of Aging

Volumn 28, Issue 9, 2007, Pages 1330-1339

  Kantarci, Kejal ^a   Weigand, Stephen D ^a   Petersen, Ronald C ^a   Boeve, Bradley F ^a   Knopman, David S ^a   Gunter, Jeffrey ^a   Reyes, Denise ^a   Shiung, Maria ^a   O'Brien, Peter C ^a   Smith, Glenn E ^a   Ivnik, Robert J ^a   Tangalos, Eric G ^a   Jack Jr , Clifford R ^a  

^a MAYO CLINIC   (United States)

Author keywords

1H MR spectroscopy; 1H MRS; Alzheimer's disease; Choline; Imaging; Longitudinal; Mild cognitive impairment; N Acetylaspartate; Serial

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; CREATINE; N ACETYLASPARTIC ACID; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; APPARATUS; ARTICLE; BRAIN VENTRICLE; CHOLINE CREATINE RATIO; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; MEASUREMENT; METABOLITE; N ACETYLASPARTATE CREATINE RATIO; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; UNITED STATES; ANALYSIS OF VARIANCE; METABOLISM; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ASPARTIC ACID; CHOLINE; COGNITION DISORDERS; CREATINE; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES;

EID: 34447580083     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.06.018     Document Type: Article

References (49)

1. Adalsteinsson E., Sullivan E.V., Kleinhans N., Spielman D.M., and Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 355 9216 (2000) 1696-1697
2. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., and Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159 5 (2002) 738-745
3. Brooks W.M., Stidley C.A., Petropoulos H., Jung R.E., Weers D.C., Friedman S.D., et al. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. J Neurotrauma 17 8 (2000) 629-640
4. Catani M., Cherubini A., Howard R., Tarducci R., Pelliccioli G.P., Piccirilli M., et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12 11 (2001) 2315-2317
5. Chantal S., Braun C.M., Bouchard R.W., Labelle M., and Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003 1-2 (2004) 26-35
6. Chao L.L., Schuff N., Kramer J.H., Du A.T., Capizzano A., O'Neill J., et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired not demented individuals. Neurology 64 (2005) 282-289
7. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., and Baron J.C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 60 8 (2003) 1374-1377
8. Choi S. Tests of equality of dependent correlations. Biometrika 64 (1977) 645-647
9. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51 2 (2002) 145-155 [see comment]
10. Dixon R.M., Bradley K.M., Budge M.M., Styles P., and Smith A.D. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125 Pt 10 (2002) 2332-2341
11. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imag 30 8 (2003) 1104-1113
12. Firbank M.J., Minett T., and O'Brien J.T. Changes in DWI and MRS associated with white matter hyperintensities in elderly subjects. Neurology 61 7 (2003) 950-954
13. Freeborough P.A., and Fox N.C. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imag 16 5 (1997) 623-629
14. Gunter J.L., Shiung M.M., Manduca A., and Jack Jr. C.R. Methodological considerations for measuring rates of brain atrophy. J Magn Reson Imag 18 1 (2003) 16-24
15. Hugg J.W., Kuzniecky R.I., Gilliam F.G., Morawetz R.B., Fraught R.E., and Hetherington H.P. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging. Ann Neurol 40 2 (1996) 236-239
16. Jack Jr. C.R., Shiung M.M., Gunter J.L., O'Brien P.C., Weigand S.D., Knopman D.S., et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62 4 (2004) 591-600
17. Jessen F., Block W., Traber F., Keller E., Flacke S., Lamerichs R., et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 57 5 (2001) 930-932
18. Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55 5 (2000) 684-688
19. Kantarci K., and Jack Jr. C. Quantitative magnetic resonance techniques as surrogate markers in Alzheimer's disease. NeuroRx J Am Soc Exp Neurotherap 1 (2004) 196-205
20. Kantarci K., Jack Jr. C.R., Xu Y.C., Campeau N.G., O'Brien P.C., Smith G.E., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 55 2 (2000) 210-217
21. Kantarci K., Petersen R., Boeve B., Knopman D., Edland S., Smith G., et al. 1H MRS in mild cognitive impairment and Alzheimer's disease; comparison of 1.5 T and 3 T. Proceedings of the 10th Scientific Meeting of the International Society for Magnetic Resonance in Medicine (2002) 971
22. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Tang-Wai D.F., O'Brien P.C., et al. 1H MR spectroscopy in common dementias. Neurology 63 8 (2004) 1393-1398 [see comment]
23. Kantarci K., Smith G.E., Ivnik R.J., Petersen R.C., Boeve B.F., Knopman D.S., et al. 1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc 8 7 (2002) 934-942
24. Kantarci K., Xu Y., Shiung M.M., O'Brien P.C., Cha R.H., Smith G.E., et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dementia Geriatr Cogn Disorders 14 4 (2002) 198-207
25. Khan O., Shen Y., Caon C., Bao F., Ching W., Reznar M., et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11 6 (2005) 646-651
26. Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J Neural Transm 107 8-9 (2000) 1027-1063
27. MacKay S., Ezekiel F., Di Sclafani V., Meyerhoff D.J., Gerson J., Norman D., et al. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology 198 2 (1996) 537-545
28. Mattis S. Dementia rating scale: professional manual (1988), Assessment Resources Inc., Odessa, Fla
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
30. Metastasio A., Rinaldi P., Tarducci R., Mariani E., Feliziani F.T., Cherubini A., et al. Conversion of MCI to dementia: role of proton magnetic resonance spectroscopy. Neurobiol Aging 27 7 (2006) 926-932
31. Michaelis T., Merboldt K.D., Bruhn H., Hanicke W., and Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 187 1 (1993) 219-227
32. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., and Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187 2 (1993) 433-437
33. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., and Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42 1 (1997) 85-94
34. Modrego P.J., Fayed N., and Pina M.A. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162 4 (2005) 667-675 [see comment]
35. Mueller S., Weiner M., Thal L., Petersen R., Jack Jr. C., Jagust W., et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's disease neuroimaging initiative (ADNI). Alzheimer's Dementia 1 1 (2005) 55-66
36. Narayanan S., De Stefano N., Francis G.S., Arnaoutelis R., Caramanos Z., Collins D.L., et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248 11 (2001) 979-986
37. O'Brien P.C. The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics 39 3 (1983) 787-794
38. Perneger T.V. What's wrong with Bonferroni adjustments. BMJ 316 7139 (1998) 1236-1238 [see comment]
39. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Arch Neurol 58 12 (2001) 1985-1992
40. Petersen R.C., Kokmen E., Tangalos E., Ivnik R.J., and Kurland L.T. Mayo clinic Alzheimer's disease patient registry. Aging-Clin Exp Res 2 4 (1990) 408-415
41. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30 6 (1993) 672-679
42. R Development Core. R: a language and environment for statistical computing (2004), R Foundation for Statistical Computing
43. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., and Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98 6 (2001) 3334-3339
44. Satlin A., Bodick N., Offen W.W., and Renshaw P.F. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an MI selective cholinergic agonist. Am J Psychiatry 154 10 (1997) 1459-1461
45. Smith G.S., de Leon M.J., George A.E., Kluger A., Volkow N.D., McRae T., et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 49 11 (1992) 1142-1150
46. Valenzuela M.J., and Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 56 5 (2001) 592-598
47. Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjogren M., et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32 6 (2001) 1318-1322
48. Webb P.G., Sailasuta N., Kohler S.J., Raidy T., Moats R.A., and Hurd R.E. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 31 4 (1994) 365-373
49. Wurtman R.J., Blusztajn J.K., and Marie J.C. Autocannibalism of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease. Neurochem Int 7 (1985) 369-372